Recent studies in preclinical mouse models, showed that PARP7 inhibition (PARP7i) with RBN-2397 reduced CT26 colon tumour growth in immunocompetent mice, which was dependent on IFN-I signalling and that cotreatment of RBN-2397 with anti-PD1 further reduced tumour growth compared with either treatment alone (33). Here, TIPARP is linked to neoplasm.